MeSH D000544 - alzheimer disease
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Memantine | Memantine |  | 2011-10-25 |  |  |
| Rivastigmine | Rivastigmine Teva |  | 2009-04-17 |  |  | |
| NATCO Pharma | Donepezil | Donepezil |  | 2011-05-31 |  |  |
| Mylan | Galantamine | Galantamine |  | 2009-05-29 |  |  |
| Memantine | Memantine Mylan |  | 2013-04-21 |  |  | |
| Rivastigmine | Rivastigmine |  | 2018-06-20 |  |  | |
| Johnson & Johnson | Galantamine | Razadyne |  | 2001-02-28 |  |  |
| Cipla | Donepezil | Donepezil |  | 2011-05-31 |  |  |
| Lupin Research | Donepezil | Donepezil |  | 2015-10-30 |  |  |
| Memantine | Memantine |  | 2015-04-10 |  |  | |
| Sandoz | Donepezil | Donepezil |  | 2011-05-31 |  |  |
| Galantamine | Galantamine |  | 2009-06-22 |  |  | |
| Rivastigmine | Rivastigmine Sandoz |  | 2009-12-10 |  |  | |
| Rivastigmine | Exelon |  | 2007-07-06 |  |  | |
| Novartis | Rivastigmine | Exelon |  | 2000-04-21 |  |  |
| Rivastigmine | Prometax |  | 1998-12-03 |  |  | |
| 3M | Rivastigmine | Rivastigmine 3M Health Care Ltd |  | 2014-04-03 |  |  |
| Bausch Health Companies | Selegiline | Zelapar |  | 2006-06-14 |  |  |
1
2
3
4
5
6
...
9
>
Clinical Trials
Historical Success Rate
Phase 1
64%74/115
Phase 2
45%71/159
Phase 3
33%42/126
Approved: 12Overall Success rate: 10%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
6
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use